Alnylam price target raised to $535 from $459 at Truist

Core Viewpoint - Truist has raised the price target for Alnylam Pharmaceuticals (ALNY) to $535 from $459 while maintaining a Buy rating ahead of the company's Q3 results [1] Group 1: Sales Estimates - The Q3 sales estimate for Amvuttra has been increased to $690 million [1] - The upward revision in forward estimates reflects strong early adoption and more rapid adoption as a first-line agent than previously expected [1] Group 2: Market Insights - Feedback from prescribers indicates that extracardiac manifestations of ATTR-CM are more widespread than previously appreciated [1]